Choose Your Country or Region

SN-38

Name: SN-38
Brand: Selleck Chemicals
SKU: S4908
Rating: 5 (45 reviews)

Catalog No.S4908 Synonyms: NK012

For research use only.

SN-38 (NK012) is an active metabolite of CPT-11, inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks. SN-38 induces autophagy.

CAS No. 86639-52-3

Selleck's SN-38 has been cited by 45 publications

Purity & Quality Control

Choose Selective ADC Cytotoxin Inhibitors

Related Compound Libraries

Biological Activity

Description

SN-38 (NK012) is an active metabolite of CPT-11, inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks. SN-38 induces autophagy.

Targets

Topo I ^[1]
(Cell-free assay)

In vitro

SN-38, a biological active metabolite of irinotecan hydrochloride (CPT-11). SN-38 causes the strongest inhibition of DNA topoisomerase I, followed by CPT and then CPT-11. CPT-11 dose dependently shifts the position of relaxed DNA in the direction of nicked DNA, but SN-38 and CPT shows no effect on the position of relaxed DNA. SN-38 dose-dependently and time-dependently inhibit DNA synthesis. Respective IC50 values of SN-38, in DNA synthesis is 0.077 μM. The inhibitory effect of SN-38 on RNA synthesis is less than that on DNA synthesis and it does not inhibit protein synthesis. SN-38 caused frequent DNA single-strand breaks in P388 cells. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

human DU145 prostate cell line	M3TNXXBzd2yrZnXyZZRqd25iYYPzZZk>			MmnyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCGVUG0OUBxem:\|dHH0[UBk\WyuIHzpcoUtKEmFNUC9NVMhdk1?	MnzFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB2OUiyNVYoRjFyNEm4NlE3RC:jPh?=
human MCF-7 breast cell line	MlH6VJJwdGmoZYLheIlwdiCjc4PhfS=>			NHTYT4dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSk04KGK{ZXHzeEBk\WyuIHzpcoUtKEmFNUC9NE4{PyEQvF2=	MljuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB2OUiyNVYoRjFyNEm4NlE3RC:jPh?=
human SKOV-3 ovarian cell line	MmjEVJJwdGmoZYLheIlwdiCjc4PhfS=>			MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONT2[tN{BwfmG{aXHuJINmdGxibHnu[UwhUUN3ME2wMlczKM7:TR?=	NXXtNIdoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC0PVgzOTZpPkGwOFk5OjF4PD;hQi=>
human breast cancer cell line (SK-BR-3)	MmniR5l1d3SxeHnjxsBie3OjeR?=			Mn3YTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZpJm[XO2IHPhcoNmeiClZXzsJIxqdmViKGPLMWJTNTNrLDDJR\|UxRTRibl2=	MoOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF\|M{S1OlkoRjFzM{O0OVY6RC:jPh?=
human lung cancer cell line (H128)	M2L1cGN6fG:2b4jpZ:Kh[XO\|YYm=			NUf1XGE1UW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdHWwZzDjZY5k\XJiY3XscEBtcW6nIDjINVI5MSxiSVO1NF03KG6P	M{n2U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{O0OVY6Lz5zMUOzOFU3QTxxYU6=
human stomach cancer cell line (MKN45)	NUjQToU4S3m2b4TvfIlkyqCjc4PhfS=>			M2DpbmlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJN1d22jY3igZ4Fv[2W{IHPlcIwhdGmwZTCoUWtPPDVrLDDJR\|UxRThibl2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTN\|NEW2PUc,OTF\|M{S1Olk9N2F-
human ovarian cancer cell line (SK-OV-3)	NFrZRXBEgXSxdH;4bYPDqGG\|c3H5			MYrJckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDveoFzcWGwIHPhcoNmeiClZXzsJIxqdmViKGPLMW9XNTNrLDDJR\|UxRTFzIH7N	M{K4ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{O0OVY6Lz5zMUOzOFU3QTxxYU6=
human colon cancer cell line (WiDr)	NHXOOHVEgXSxdH;4bYPDqGG\|c3H5			NXvDfYk2UW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[2:ub36gZ4Fv[2W{IHPlcIwhdGmwZTCoW4lFeiluIFnDOVA:OTRibl2=	NF:xTFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOzOFU3QSd-MUGzN\|Q2Pjl:L3G+
human lung cancer cell line (A549)	NFz6dGlEgXSxdH;4bYPDqGG\|c3H5			NWjmbnJ3UW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdHWwZzDjZY5k\XJiY3XscEBtcW6nIDjBOVQ6MQ>?	NX;uTJNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzN\|Q2PjlpPkGxN\|M1PTZ7PD;hQi=>
NSCLC-H460	M{XNWWN6fG:2b4jpZ:Kh[XO\|YYm=			NI\NNVREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBvd25vc33hcIwu[2WubDDseY5oKGOjcnPpco9u[SClZXzsJIxqdmViSES2NEApVlOFTFOtTFQ3OCluIFnDOVA:QDBibl2=	M{XvcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzNU[zPVI2Lz5zMUW2N\|kzPTxxYU6=
PC-3 carcinoma cell line	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MlfUR49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IHfyc5d1cCCxZjDoeY1idiCycn;zeIF1\SCSQz2zJINiemOrbn;tZUBk\WyuIHzpcoUtKEmFNUC9N\|UvPiCwTR?=	NF73SY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUS1OFI{OCd-MUW0OVQzOzB:L3G+
human HCT116 colon cancer cell line	MlfMSpVv[3Srb36gZZN{[Xl?			NFvuNZJKdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2:ub36gZ4Fv[2W{IHPlcIwhdGmwZTygTWM2OD15IH7N	NYTaWmF2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW4NFg1PTZpPkG1PFA5PDV4PD;hQi=>
human Bel-7402 liver cancer cell line	MWHGeY5kfGmxbjDhd5NigQ>?			M4rxSWlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IHj1cYFvKEKnbD23OFAzKGyrdnXyJINidmOncjDj[YxtKGyrbnWsJGlEPTB;Mz6xPUDPxE1?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPThyOES1Okc,OTV6MEi0OVY9N2F-
human tumor HL60 cell-line	MWfGeY5kfGmxbjDhd5NigQ>?		M{XqVFMh\GG7cx?=	NUnIWlBNUW5vdnn0do8hcW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIZweiCqdX3hckB1fW2xcjDIUFYxKGOnbHytcIlv\SC5YYOg[IV1\XKvaX7l[EB2e2mwZzDTVmIh[XO\|YYmgZYZ1\XJiMzDkZZl{KG:oIHnuZ5Vj[XSrb36sJGlEPTB;MUmgcm0>	NWXhe2JORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW5NVM6QTZpPkG1PVE{QTl4PD;hQi=>
human H460 cell	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M{TUbmlvcGmkaYTpc44hd2ZiaIXtZY4hUDR4MDDj[YxtKGe{b4f0bEwhUUN3ME24NEBvVQ>?	NYLxd5BYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5NVM4ODZpPkG2PVE{PzB4PD;hQi=>
MDA-MB-435	MkDoSpVv[3Srb36gZZN{[Xl?			NIPuXYhKdmirYnn0bY9vKGGpYXnud5QhVUSDLV3CMVQ{PSCVIHj1cYFvKGK{ZXHzeEBk[W6lZYKgZ4VtdHNiaX6geIhmKGGkc3XuZ4Uhd2ZiYXzieY1qdixiSVO1NEA:KDBwMEC1JO69VS5?	NFi4UpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUC1NlgxOid-MUGwOVI5ODJ:L3G+
MDA-MB-435	NHfKTldHfW6ldHnvckBie3OjeR?=			NX7I[ZU{UW6qaXLpeIlwdiCjZ3HpcpN1KE2GQT3NRk01OzViUzDoeY1idiCkcnXhd5Qh[2GwY3XyJINmdGy\|IHnuJJRp\SCycnXz[Y5k\SCxZjCzNEBu\y:vTDDIV2EtKEmFNUCgQUAxNjB3IN88UU4>	NF36WXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUC1NlgxOid-MUGwOVI5ODJ:L3G+
PC-6/SN2-5H	NFLiNZJHfW6ldHnvckBie3OjeR?=			NVO3[YozXFChVGLBUnNRV1KWRWK6JJVxfGGtZTDpckBu\W2kcnHu[UB3\XOrY3zlJIZzd21iUFOtOk9UVjJvNVigZ4VtdHNuIFvtJF0hPCEQvF2u	NE\oUIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMU[4PFk5Oid-MUG2PFg6QDJ:L3G+
HT-29	M331RmZ2dmO2aX;uJIF{e2G7			NWnvVWkzUW5idnn0do8hcW6qaXLpeI9zgSClb37j[Y51emG2aX;uJJJmeXWrcnXkJIFo[Wmwc4SgTHQuOjliaIXtZY4h[2:ub36gZ4Fv[2W{IHPlcIx{NCCLQ{WwJF0hOC5yMkezJO69VS5?	NGPq[Gs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMk[xO\|kzPyd-MUK2NVc6Ojd:L3G+
SaoS2	Ml;vSpVv[3Srb36gZZN{[Xl?			M4PHWXRRZ1SUQV7TVG9TXEWUOjDkdpVoKHKnc3nzeIFv[2VqSX3heIlvcWJibXXzfYxifGVrIHnuJGJEWlBvZYjwdoV{e2mwZzDTZY9UOiClZXzsd{whUUN3MDC9JFAvOTd4IN88UU4>	NGjBS\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUC1PVg5OSd-MUWwOVk5QDF:L3G+
DU145	MV\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MVK5OkBpenN?	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy\|IHHmeIVzKDl4IHjyd{whUUN3MDC9JFAvODB2IN88UU4>	M{fnTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Mke2NVQyLz5zOEK3OlE1OTxxYU6=
MIA PaCa	MknhRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M2SyVVk3KGi{cx?=	NGW3OJFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3JRUBR[UOjIHPlcIx{KGGodHXyJFk3KGi{czygTWM2OCB;IECuNFA3KM7:TT6=	NELUSYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK3OlE1OSd-MUiyO\|YyPDF:L3G+
HT29	NGfJbpFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M4O5W\|k3KGi{cx?=	NYnWNlUxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWFI6KGOnbHzzJIFnfGW{IEm2JIhzeyxiSVO1NEA:KDBwMEGyJO69VS5?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ5NkG0NUc,OTh{N{[xOFE9N2F-
H460	MkjwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXvDeYJPOSCqch?=	MmLCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKNE[wJINmdGy\|IHHmeIVzKDFiaIKgc4Yh\HK3ZzDlfJBwe3W{ZTDt[YF{fXKnZDDh[pRmeiB5MjDodpMtKEmFNUCgQUAxNjJ{IN88UU4>	NUPFXYVVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0NlQyOzNpPkG4OFI1OTN\|PD;hQi=>
HT29	NXW2fllJSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3fzVVEhcHJ?	NXXneoxESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWFI6KGOnbHzzJIFnfGW{IEGgbJIhd2ZiZIL1[{BmgHCxc4Xy[UBu\WG\|dYLl[EBi\nSncjC3NkBpenNuIFnDOVAhRSByLk[3JO69VS5?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR{NEGzN{c,OTh2MkSxN\|M9N2F-
HT29	MkHlRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MXyxJIhz	M4HlUmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgRmNTWCCxdnXy[ZhxemW\|c3nu[{BucXSxeHHueJJwdmVvcnXzbZN1[W62IHj1cYFvKEiWMkmgZ4VtdHNiYX\0[ZIhOSCqcjDv[kBlenWpIHX4dI9{fXKnIH3lZZN2emWmIHHmeIVzKDd{IHjyd{whUUN3MDC9JFEyNjVizszNMi=>	NX\3NIpQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0NlQyOzNpPkG4OFI1OTN\|PD;hQi=>
H460	NVezRpNqS3m2b4TvfIlkcXS7IHHzd4F6			M{L5dGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGg1PjBiY3XscJMtKEmFNUCgQUAxNjJ{IN88UU4>	NX\xbWpRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0N\|QyPTNpPkG4OFM1OTV\|PD;hQi=>
A549	Mlf3R5l1d3SxeHnjbZR6KGG\|c3H5			M4\UWGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[nliU2LCJI1mfGixZDygTWM2OCB;IECuNFgh\|ryPLh?=	M1yzbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUi2PFA4Lz5zOEm4OlgxPzxxYU6=
HT-29	MoKwR5l1d3SxeHnjbZR6KGG\|c3H5			M2jDWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{KGK7IGPSRkBu\XSqb3SsJGlEPTBiPTCwMlEzKM7:TT6=	M2TDTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUi2PFA4Lz5zOEm4OlgxPzxxYU6=
PC6	MoDuRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M{HWUlYh\GG7cx?=	MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFNjDj[YxteyClYYLyfYlv\yCyUlOgZYZ1\XJiNjDkZZl{NCCLQ{WwJF0hOC5yMEC0N{DPxE1w	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ3NEi0N{c,OTl{NUS4OFM9N2F-
HCT116	Mn3GRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M2naOFMh\GG7cx?=	MnnRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiMzDkZZl{NCCLQ{WwJF0hOC5yMEC1OUDPxE1w	NF\DTWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUK1OFg1Oyd-MUmyOVQ5PDN:L3G+
QG56	NXjlNVB{SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NWjXV4RyOyCmYYnz	M{HPSGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUVe1OkBk\WyuczDh[pRmeiB\|IHThfZMtKEmFNUCgQUAxNjByMkig{txONg>?	M3e0clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW0PFQ{Lz5zOUK1OFg1OzxxYU6=
NCI-H460	M1\jSmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NHzkRlI{KGSjeYO=	NHK1fYJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPDZyIHPlcIx{KGGodHXyJFMh\GG7czygTWM2OCB;IECuNFA{OyEQvF2u	M1TXelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW0PFQ{Lz5zOUK1OFg1OzxxYU6=
BCRP	MmfzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M3zrclYh\GG7cx?=	MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFNjDlfJBz\XO\|aX7nJGJEWlBiY3XscJMh[W[2ZYKgOkBl[Xm\|LDDJR\|UxKD1iMD6wNFUyKM7:TT6=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ3NEi0N{c,OTl{NUS4OFM9N2F-
KB3-1	NHTSV3pEgXSxdH;4bYNqfHliYYPzZZk>		M{HY[lQh\GG7cx?=	NVjjO49zS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0J\|LUGgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KE2WVDDt[ZRpd2RuIFnDOVAhRSByLkCwOEDPxE1w	M{PZdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{CzN\|A3Lz5zOUOwN\|MxPjxxYU6=
KBV1	Mni4R5l1d3SxeHnjbZR6KGG\|c3H5		M2ixWFQh\GG7cx?=	MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBOTFJzIH;2[ZJmgHC{ZYPzbY5oKGi3bXHuJGtDXjFiY3XscJMh[W[2ZYKgOEBl[Xm\|IHL5JG1VXCCvZYToc4QtKEmFNUCgQUAxNjB2NjFOwG0v	NWjlNZZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzNFM{ODZpPkG5N\|A{OzB4PD;hQi=>
KBH5.0	M2DzfWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M2jadVQh\GG7cx?=	NFrpfHpEgXSxdH;4bYNqfHliYXfhbY5{fCCEQ2LQJI93\XKneIDy[ZN{cW6pIHj1cYFvKEuESEWuNEBk\WyuczDh[pRmeiB2IHThfZMh[nliTWTUJI1mfGixZDygTWM2OCB;IECuN{DPxE1w	MofRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|MEOzNFYoRjF7M{CzN\|A3RC:jPh?=
NCI-H460	MkixRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MYmxJIhz	NEPkNlhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPDZyIHPlcIx{KGGodHXyJJNpd3K2IITldo0h\Xiyb4P1doUh\m:{IEGgbJIhdWWjc4Xy[YQh[W[2ZYKgO\|IhcHK\|IHnuJIRzfWdvZoLl[UBu\WSrdX2sJGlEPTBiPTCwMlE{KM7:TT6=	NF;tO4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUWzNFczOCd-MUm1N\|A4OjB:L3G+
A549/ATCC	MoDxRY51cXS3bX;yJIF{e2G7			NEjGZodCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6N0GWQ1OgZ4VtdHNiYomgV3JDKG2ndHjv[EwhUUN3MDC9JFAvODh6IN88UU4>	M1rzeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUSxOFg{Lz5zOUW0NVQ5OzxxYU6=
HT-29	M3vXWGFvfGm2dX3vdkBie3OjeR?=			MWTBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKVD2yPUBk\WyuczDifUBUWkJibXX0bI9lNCCLQ{WwJF0hOC5zNzFOwG0v	MlzxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3NEG0PFMoRjF7NUSxOFg{RC:jPh?=
gastric cancer cells	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmDYO\|IhcHK\|	NWXEb29IT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h\2G\|dILpZ{Bk[W6lZYKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO\|YYmsJGdKPTBiPTCwMlA3PiEQvF2u	NGXtTXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi4OFA5QSd-MkC4PFQxQDl:L3G+
lung cancer cells	M2DtPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NW\iPHZQPzJiaILz	NES0O5VIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBtfW6pIHPhcoNmeiClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NEA:KDBwME[2JO69VS5?	Mnf0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OESwPFkoRjJyOEi0NFg6RC:jPh?=
colon cancer cells	MlrCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWTub\|h{PzJiaILz	MVjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDjc4xwdiClYX7j[ZIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUCgQUAxNjB4NjFOwG0v	M2PEU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEi0NFg6Lz5{MEi4OFA5QTxxYU6=
HT-29	M1;qUmN6fG:2b4jpZ4l1gSCjc4PhfS=>			NH;RN4ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyxiSVO1NEA:KDBwMEC1PUDPxE1w	MlfSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2N{C4OlQoRjJzNEewPFY1RC:jPh?=
A549	M1PtZ2N6fG:2b4jpZ4l1gSCjc4PhfS=>			NVz4[4FHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyxiSVO1NEA:KDBwMES3JO69VS5?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR5MEi2OEc,OjF2N{C4OlQ9N2F-
PC3	MVnDfZRwfG:6aXPpeJkh[XO\|YYm=		MoS5O\|IhcHK\|	MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOg[ZhxemW\|c3nu[{BidHCqYUXi[ZRiOyCrboTl[5JqdiCjc4Pld5Nm\CCjczDj[YxtKHO3co\peoFtKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjByMk[g{txONg>?	MoG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NUmyOFYoRjJ{OUW5NlQ3RC:jPh?=
A2780	MonwR5l1d3SxeHnjbZR6KGG\|c3H5		NHvtS3o4OiCqcoO=	NFqzT\|NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCxdnXy[ZhxemW\|c3nu[{BidHCqYUXi[ZRiOyCrboTl[5JqdiCjc4Pld5Nm\CCjczDj[YxtKHO3co\peoFtKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjByOTFOwG0v	MlziQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NUmyOFYoRjJ{OUW5NlQ3RC:jPh?=
DU145	NUXyTVg{S3m2b4TvfIlkcXS7IHHzd4F6			NIPnT\|NEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyxiSVO1NEA:KDBwMEOg{txONg>?	Mn3vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3N{i1OFUoRjJ\|NUe4OVQ2RC:jPh?=
HT-29	NVvtUopwS3m2b4TvfIlkcXS7IHHzd4F6			NXj6[INHS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNuIFnDOVAhRSByLkCzJO69VS5?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV5OEW0OUc,OjN3N{i1OFU9N2F-
L1210	M2XjdGN6fG:2b4jpZ4l1gSCjc4PhfS=>			NFTPd3JEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBNOTJzMDDj[YxteyxiSVO1NEA:KDBwMESg{txONg>?	NInld5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W3PFU1PSd-MkO1O\|g2PDV:L3G+
DU145	NVq0eHJjS3m2b4TvfIlkcXS7IHHzd4F6		MmfJO\|IhcHK\|	MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSByLkGxJO69VS5?	NF23b3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[yNlk5OSd-MkO2NlI6QDF:L3G+
DU145	Mlq5SpVv[3Srb36gZZN{[Xl?	NYHCemdtOC5zIITvJFAvPSC3TR?=	Ml7qNlQhcHK\|	NXS2bFAzUW6qaXLpeIlwdiCxZjDISGFEKGmwIHj1cYFvKESXMUS1JINmdGy\|IHHzd4V{e2WmIHHzJJVxemWpdXzheIlwdiCxZjDwNlF4[WZzIHX4dJJme3Orb36gZZQhOC5zIITvJFAvPSC3TTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ{Mkm4NUc,OjN4MkK5PFE9N2F-
A549	MWDDfZRwfG:6aXPpeJkh[XO\|YYm=		NGnx[nk{KGSjeYO=	MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFMh\GG7czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjByMkeyJO69VS5?	NFvJcpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyPVg4OCd-MkS1Nlk5PzB:L3G+
HCT116	MUfDfZRwfG:6aXPpeJkh[XO\|YYm=		M1PO[VMh\GG7cx?=	NYjtN4pNS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEOg[IF6eyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlA{OSEQvF2u	NEfjb5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyPVg4OCd-MkS1Nlk5PzB:L3G+
HT-29	NX[0fmJmS3m2b4TvfIlkcXS7IHHzd4F6		M3z3XVMh\GG7cx?=	MnS0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhOyCmYYnzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDBwMUC2Olch\|ryPLh?=	NHvFNW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyPVg4OCd-MkS1Nlk5PzB:L3G+
HCT116	MX\DfZRwfG:6aXPpeJkh[XO\|YYm=			MlLJR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{NCCLQ{WwJF0hOC5zNk[g{txONg>?	NWK3T2lmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1Nlk5PzBpPkK0OVI6QDdyPD;hQi=>
MDA-MB-231	M17lfGN6fG:2b4jpZ4l1gSCjc4PhfS=>			MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|LDDJR\|UxKD1iMD6xO\|Yh\|ryPLh?=	NXnIbIljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1Nlk5PzBpPkK0OVI6QDdyPD;hQi=>
A549	NV\3W\|VJS3m2b4TvfIlkcXS7IHHzd4F6			NIP4bpFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{NCCLQ{WwJF0hOC5{NUmg{txONg>?	NGLre5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyPVg4OCd-MkS1Nlk5PzB:L3G+
HEK293	MlfqR5l1d3SxeHnjbZR6KGG\|c3H5		M3PrZ\|czKGi{cx?=	MoTnTY51emmwc3njJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUd3MDC9JFAvODB3IN88UU4>	M4ryVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkeyNFU2Lz5{NUK3NlA2PTxxYU6=
HCT116	NIDOdZdEgXSxdH;4bYNqfHliYYPzZZk>		MmK0O\|IhcHK\|	M4W4dWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygTWM2OCB;IECuNFA1OjhizszNMi=>	NV62PGp3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|U{PTlpPkK1PFM2OzV7PD;hQi=>
HT-29	MVHDfZRwfG:6aXPpeJkh[XO\|YYm=		M{nuUFczKGi{cx?=	NE\odlhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygTWM2OCB;IECuNFE5PTRizszNMi=>	MofKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{WzOVkoRjJ3OEO1N\|U6RC:jPh?=
HCT15	MXLDfZRwfG:6aXPpeJkh[XO\|YYm=		M1n1eVczKGi{cx?=	NYLL[oxoS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUWgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFA5KM7:TT6=	NEO1flE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C2NFc3OCd-MkewOlA4PjB:L3G+
U251	MnywR5l1d3SxeHnjbZR6KGG\|c3H5		M2LsclczKGi{cx?=	MkjFR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVI2OSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5yMkGg{txONg>?	NE\3PW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C2NFc3OCd-MkewOlA4PjB:L3G+
U87MG	MmLUR5l1d3SxeHnjbZR6KGG\|c3H5		M3LldVczKGi{cx?=	NVrwcmQ5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTh5TVegZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFMh\|ryPLh?=	M33WZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO\|YxLz5{N{C2NFc3ODxxYU6=
HT-29	Ml;WR5l1d3SxeHnjbZR6KGG\|c3H5		NV3jRVQ1PzJiaILz	MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5yNUSg{txONg>?	NVPtO3dCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewOlA4PjBpPkK3NFYxPzZyPD;hQi=>
MCF7	NYP1UIdyS3m2b4TvfIlkcXS7IHHzd4F6		NIHkSWo4OiCqcoO=	MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjVzNTFOwG0v	MoPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyNkC3OlAoRjJ5ME[wO\|YxRC:jPh?=
MDA-MB-231	MXLDfZRwfG:6aXPpeJkh[XO\|YYm=		NXnoUmFqPzJiaILz	NYXRdWx{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOS57NzFOwG0v	NYOxNZFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewOlA4PjBpPkK3NFYxPzZyPD;hQi=>
NCI-H460	NU\ZW3d6S3m2b4TvfIlkcXS7IHHzd4F6		NFzhRnAzPCCqcoO=	MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCycnX0doVifGWmIH\vdkAzPCCqcoOgeY5l\XJibn;ycY95cWNiY3;u[Il1cW:wIH\vcIxwf2WmIHL5JINwdXCxdX7kJJdie2ixdYSgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFUh\|ryPLh?=	NYrBTpB1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOVA6QTdpPkK4N\|UxQTl5PD;hQi=>
NCI-H460	MUPDfZRwfG:6aXPpeJkh[XO\|YYm=		MYiyOEBpenN?	MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCycnX0doVifGWmIH\vdkAzPCCqcoOgeY5l\XJiaInwc5hq[yClb37kbZRqd25iZn;scI94\WRiYomgZ49ueG:3bnSge4F{cG:3dDDt[YF{fXKnZDDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wOkDPxE1w	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN3MEm5O{c,Ojh\|NUC5PVc9N2F-
HT-29	MkDrR5l1d3SxeHnjbZR6KGG\|c3H5		MYeyOEBpenN?	M1rUemN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{KHC{ZYTy[YF1\WRiZn;yJFI1KGi{czD1coRmeiCwb4Ltc5hq[yClb37kbZRqd25iZn;scI94\WRiYomgZ49ueG:3bnSge4F{cG:3dDDt[YF{fXKnZDDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMj63OEDPxE1w	NVTPVZVwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOVA6QTdpPkK4N\|UxQTl5PD;hQi=>
HT-29	NV\qb5JVS3m2b4TvfIlkcXS7IHHzd4F6		NWLaeHhPOjRiaILz	MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{BxemW2cnXheIVlKG[xcjCyOEBpenNidX7k[ZIhcHmyb4jpZ{Bkd26maYTpc44h\m:ubH;3[YQh[nliY3;tdI92dmRid3HzbI92fCCvZXHzeZJm\CCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOy55MTFOwG0v	NYi1Tmk2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOVA6QTdpPkK4N\|UxQTl5PD;hQi=>
NCI-H460	MXHDfZRwfG:6aXPpeJkh[XO\|YYm=		NV;hPJdHPzJiaILz	MkK2R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIILl[JVkfGmxbjD1coRmeiCqeYDvfIlkKGOxbnTpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yNEeg{txONg>?	NVfnToxrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OFA3OTNpPkK4O\|QxPjF\|PD;hQi=>
NCI-H460	Ml;mR5l1d3SxeHnjbZR6KGG\|c3H5		MmrCO\|IhcHK\|	NUjhXnZOS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVi0OlAh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJJJm\HWldHnvckB2dmSncjDuc5Jud3irYzDjc45lcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFUh\|ryPLh?=	NVLqd5pTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OFA3OTNpPkK4O\|QxPjF\|PD;hQi=>
HT-29	MmnkR5l1d3SxeHnjbZR6KGG\|c3H5		NIP6[\|U4OiCqcoO=	NFzvboJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhicnXkeYN1cW:wIIXu[IVzKG6xcn3vfIlkKGOxbnTpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yOU[g{txONg>?	M2fsfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{SwOlE{Lz5{OEe0NFYyOzxxYU6=
HT-29	M2fRV2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M1jJXFczKGi{cx?=	NXL6b2lPS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIILl[JVkfGmxbjD1coRmeiCqeYDvfIlkKGOxbnTpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5zMUmg{txONg>?	Ml3kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5NEC2NVMoRjJ6N{SwOlE{RC:jPh?=
TC32	MmS2dWhVWyCjc4PhfS=>			MUHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	M3WwXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	M4TQPJFJXFNiYYPzZZk>			MYTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	NH2x[3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	MlfrdWhVWyCjc4PhfS=>			NULlTYJ7eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO=	MmW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	M4H0PZFJXFNiYYPzZZk>			NUjJcGhKeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	NW[0RpBSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	MXjxTHRUKGG\|c3H5			MVvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN?	NFj6PFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	M4XZdZFJXFNiYYPzZZk>			NVL6U2s3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLEJINmdGy\|	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	M{jEVpFJXFNiYYPzZZk>			MnfndWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-12	NGfEe3dyUFSVIHHzd4F6			NF;1cVhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO=	NYmze2tURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	NEe4PXlyUFSVIHHzd4F6			MY\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN?	M3:wOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	NELtZlNyUFSVIHHzd4F6			NF3nO21yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	MnPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	NX;Meo9oeUiWUzDhd5NigQ>?			M4jjcpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-12	NHzZWmtyUFSVIHHzd4F6			MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0yOiClZXzsdy=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	NGL6RpRyUFSVIHHzd4F6			MnzFdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN?	NWCwcINJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	Mlj0dWhVWyCjc4PhfS=>			MkHadWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIuTUKlMTDj[Yxtew>?	NGfSVYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	MXrxTHRUKGG\|c3H5			NFPIWoRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLWPIJINmdGy\|	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh30	MYHxTHRUKGG\|c3H5			M2fWOpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy\|	M{iydlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	NE\aTpVyUFSVIHHzd4F6			MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=>	NInwUG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh30	M1u3bJFJXFNiYYPzZZk>			Mom0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog{OCClZXzsdy=>	MmfOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS	NWTFSJhUeUiWUzDhd5NigQ>?			M4fORpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHUuOiCRUzDj[Yxtew>?	M3jaN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	MmDmdWhVWyCjc4PhfS=>			M3yzZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJM>	NXvq[FdGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	MmjSdWhVWyCjc4PhfS=>			M3;nPJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	NUK3cWVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	MVLxTHRUKGG\|c3H5			MonhdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	M{jlSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	M{f0epFJXFNiYYPzZZk>			MorXdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	Mn\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	MUDxTHRUKGG\|c3H5			M3vZU5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?=	NULNfVdnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	MmDUdWhVWyCjc4PhfS=>			NV:4U2RxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	NUPmUZJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
HCT116	M4O0WWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NEPwVlI4OiCqcoO=	NVXYS4RCSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFAvODByN{ig{txONg>?	NFTibZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEGxOVQ6Oid-M{CxNVU1QTJ:L3G+
A549	MWnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M4HjWFczKGi{cx?=	NIPBVlNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFAyPjJizszNMi=>	NIjXNXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEGxOVQ6Oid-M{CxNVU1QTJ:L3G+
MCF7	M3HKVmN6fG:2b4jpZ4l1gSCjc4PhfS=>		Mo\JO\|IhcHK\|	NXX4ZpNVS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygTWM2OCB;IECuNFAxOSEQvF2u	Ml\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzNkmwN\|goRjNyMU[5NFM5RC:jPh?=
A549	MXnDfZRwfG:6aXPpeJkh[XO\|YYm=		NXzndWF7PzJiaILz	MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCLQ{WwJF0hOC5{IN88UU4>	NHXjbHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEG2PVA{QCd-M{CxOlkxOzh:L3G+

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	p-Chk1 / Chk1 / Topo I	18509065
Growth inhibition assay	Cell viability	25759163

In vivo

After oral dosing, peak SN-38 concentrations occurrs within 1 h, and the The percent unbound SN-38 lactone in murine plasma at 1000 ng/mL is 3.4 +/- 0.67%, whereas at 100 ng/mL the percent unbound is 1.18 +/- 0.14%. SN-38 lactone AUCs in micebearing human neuroblastoma xenografts are greater than in nontumor-bearing animals. ^[2]

Protocol (from reference)

Kinase Assay:^[1]

Topoisomerase I Assay:
One unit (the minimum amount for full relaxation of 0.5 μg SV40 DNA under the conditions of this study) of topoisomerase I, 0.5 μL of the test compounds, and 0.5μg SV40 DNA are added sequentially to the reaction buffer, which is composed of 25 mM Tris-HCl (pH 7.5), 50 mM KC1, 5 mM MgCl₂, 0.25 mM EDTA disodium salt, 0.25 mM dithiothreitol, 15μg /mL bovine serum albumin, and 5% glycerol. Then, the reaction mixture (50 μL) is incubated for 10 min at 37 °C, and the reaction is terminated by treatment with 7.5 μL of a solution consisting of 1% sodium dodecyl sulfate, 20 mM EDTA disodium salt, and 0.5 mg/mL proteinase K for an additional 30 min at 37°C. The samples are mixed with 5 μL of the loading buffer containing 10 mM Na₂HPO₄, 31.3% sucrose, and 0.3% bromophenol blue. Relaxed (form Ir) DNA is separated from supercoiled (form I) and nicked (form II) DNA by electrophoresis on 0.8% agarose gel at 50 mA and 20 V for 17 h in the presence of 2 μg/mL chloroquine, 10 mM EDTA, 30 mM NaH₂PO₄, and 36 Mm Tris-HCl (pH 7.8). After electrophoresis, the gel is stained with 0.05% ethidium bromide and photographed with UV light (302 nm). The amount of DNA is quantified using a densitometer.

Cell Research:^[3]

Cell lines: A-172, U-87, and LA-567
Concentrations: 0 -1000 nM
Incubation Time: 48 h
Method: MTT assay

References

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight	392.4
Formula	C₂₂H₂₀N₂O₅
CAS No.	86639-52-3
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)O

Download SN-38 SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05101096	Recruiting	Drug: Sacituzumab Govitecan-hziy	Advanced Solid Tumors or Triple-negative Breast Cancer	Gilead Sciences	October 20 2021	Phase 1\|Phase 2
NCT04866641	Recruiting	Drug: T-1201 Injection 100 mg Kit	Advanced Solid Tumor	Taivex Therapeutics Corporation	June 24 2021	Phase 1
NCT04617522	Recruiting	Drug: Sacituzumab Govitecan-hziy	Advanced or Metastatic Solid Tumor\|Liver Failure	Gilead Sciences	April 6 2021	Phase 1
NCT03995706	Recruiting	Drug: Sacituzumab Govitecan	Glioblastoma	The University of Texas Health Science Center at San Antonio\|Gilead Sciences	July 17 2019	Early Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):